| Literature DB >> 30286268 |
Leyun Xie1, Bing Zhang1, Niguang Xiao1, Fei Zhang1, Xin Zhao1, Qin Liu1, Zhiping Xie2, Hanchun Gao2, Zhaojun Duan2, Lili Zhong1.
Abstract
To investigate the current genotypes of circulating human adenovirus (HAdV) strains, we molecularly genotyped HAdV in the nasopharyngeal aspirates (NPAs) of patients with acute lower respiratory tract infections (ALRTIs) and attempted to determine their associations with clinical symptoms. A total of 4751 NPA samples were collected from 4751 patients admitted to Hunan Provincial People's Hospital from September 2007 to March 2014, of which 447 (9.4%) samples were HAdV positive. Fourteen different HAdV types were identified; HAdV types 1 to 7 (HAdV 1-7) were identified in 95.7% of the 447 NPA samples with HAdV-7 and HAdV-3 being the most prevalent. In addition, 93.3% (417 of 447) of patients were younger than 5 years. The incidence of HAdV infection peaked in summer. Different HAdV types showed a predilection for different age groups and different seasonal distribution patterns. Coinfection of HAdVs and other respiratory viruses was detected in 63.3% (283 of 447) of the HAdV-positive samples. The most common clinical diagnosis was pneumonia and the most common symptoms were fever and cough. In comparison with children infected with HAdV-3 alone, those infected with HAdV-7 alone had an increased frequency of severe pneumonia involvement (11.6% vs 32.4%; P = 0.031), higher intensive care unit admission rates (7.0% vs 26.5%; P = 0.019), and a longer length of hospital stay (P = 0.03). Mixed infections in younger children were associated with a longer hospital stay (P = 0.023). Our results demonstrate the recent changes in the trends of circulating HAdV genotypes associated with ALRTIs in Hunan China.Entities:
Keywords: acute lower respiratory tract infection; adenovirus; children; hospitalization; polymerase chain reaction
Mesh:
Year: 2018 PMID: 30286268 PMCID: PMC7159165 DOI: 10.1002/jmv.25333
Source DB: PubMed Journal: J Med Virol ISSN: 0146-6615 Impact factor: 2.327
Figure 1A, Monthly distribution of cases of HAdV infection during the study period. B, Seasonal distribution of cases of HAdV infection between September 2007 and March 2014. HAdV, human adenovirus
Demographic data and clinical characteristics of hospitalized children with lower respiratory tract infection associated with adenovirus, according to the type
| Characteristics | HAdV‐1, n = 33, % | HAdV‐2, n = 24, % | HAdV‐3, n= 97, % | HAdV‐7, n = 90, % | HAdV‐4, n = 10, % | Other type, n = 25, % | Total, n = 279, % |
|---|---|---|---|---|---|---|---|
| Age, IQR, mo | 24 (8‐35) | 23 (9.2‐37.5) | 20 (8.5‐38.5) | 18.5 (9‐36) | 10 (8‐17) | 11 (8‐20) | 20 (9‐37) |
| Male | 21 (63.6) | 15 (62.5) | 58 (59.7) | 52 (57.8) | 9 (90.0) | 20 (80.0) | 175 (62.7) |
| Most common diagnostic terms | |||||||
| Pneumonia | 28 (84.9) | 15 (62.5) | 83 (85.6) | 80 (88.9) | 9 (90.0) | 22 (88.0) | 237 (85.0) |
| Bronchiolitis | 4 (12.1) | 5 (20.8) | 5 (5.2) | 4 (4.4) | 0 | 0 | 18 (6.5) |
| Bronchitis | 1 (3.0) | 4 (16.7) | 9 (9.3) | 6 (6.7) | 1 (10.0) | 3 (8.0) | 24 (8.6) |
| Underlying disease | 0 | 0 | 5 (5.2) | 5 (5.6) | 0 | 3 (12.0) | 13 (4.7) |
| Outcome LOS, median (IQR), d | 5 (6‐8) | 6 (5‐7.75) | 7 (6‐9.5) | 9 (7‐11) | 6 (6‐7.75) | 8 (6.75‐10) | 7 (6‐10) |
| Coinfection | 22 (66.7) | 19 (79.2) | 54 (55.7) | 56 (62.2) | 2 (20.0) | 23 (92.0) | 175 (62.7) |
| Chest radiopraphic finding: consolidation | 1 (3.0) | 0 | 12 (12.4) | 28 (31.1) | 0 | 3 (12.0) | 44 (15.8) |
| Severe pneumonia | 3 (9.1) | 1 (4.2) | 11 (11.3) | 30 (33.3) | 0 | 4 (16.0) | 49 (17.6) |
| Admission to ICU | 1 (3.0) | 1 (4.2) | 5 (5.2) | 17 (33.3) | 0 | 1 (4.0) | 25 (9.0) |
Abbreviations: ICU, intensive care unit; IQR, interquartile range; LOS, length of hospital stay.
Clinical manifestations from hospitalized children infected with lower respiratory tract infection associated with adenovirus, according to the type
| Characteristics | HAdV‐1, n = 33, % | HAdV‐2, n = 24,% | HAdV‐3, n = 97, % | HAdV‐7, n = 90,% | HAdV‐4, n = 10,% | Other types, n = 25, % | Total, n |
|---|---|---|---|---|---|---|---|
| Fever | 18 (54.6) | 16 (66.7) | 77 (79.4) | 77 (85.6) | 8 (80.0) | 19 (76.0) | 215 (77.1) |
| High fever, temperature >39°C | 7 (21.2) | 9 (37.5) | 44 (45.4) | 56 (62.2) | 6 (60.00) | 13 (52.00) | 135 (48.4) |
| Duration of fever, IQR, d | 3 (1.5‐5) | 4 (3‐6.75) | 5 (4‐7) | 7 (5‐11.5) | 4.5 (25‐5.5) | 6 (3.75‐8.75) | 6 (4‐9) |
| Duration of fever >7 d | 3 (9.1) | 3 (12.5) | 18 (18.6) | 32 (35.6) | 1 (10.0) | 6 (24.0) | 63 (22.9) |
| Cough | 31 (93.9) | 24 (100.0) | 87 (89.7) | 85 (94.4) | 10 (100.0) | 23 (92.0) | 260 (93.2) |
| Wheezing | 14 (42.4) | 7 (29.2) | 37 (38.1) | 36 (40.0) | 1 (10.0) | 11 (44.0) | 106 (38.0) |
| Cyanosis | 0 | 1 (4.2) | 6 (6.2) | 10 (11.1) | 0 | 2 (8.0) | 19 (6.8) |
| Tachypnea | 3 (9.1) | 1 (4.2) | 16 (16.5) | 17 (18.9) | 0 | 5 (20.0) | 42 (15.1) |
| Rales | 29 (87.9) | 20 (83.3) | 80 (82.5) | 84 (93.3) | 10 (100.0) | 22 (88.0) | 245 (87.8) |
| Decreased breath sounds | 0 | 0 | 6 (6.2) | 8 (9.0) | 0 | 0 | 14 (5.0) |
| Extrapulmonary manifestations | 0 | ||||||
| Diarrhea | 1 (3.0) | 4 (16.7) | 11 (11.3) | 17 (18.9) | 0 | 1 (4.0) | 34 (12.2) |
| Vomiting | 0 | 1 (4.2) | 11 (11.3) | 14 (15.6) | 1 (10.00) | 0 | 27 (9.7) |
| Rash | 1 (3.0) | 3 (12.5) | 9 (9.3) | 12 (13.3) | 0 | 0 | 25 (9.0) |
| Seizure | 1 (3.0) | 2 (8.3) | 2 (2.1) | 1 (1.1) | 0 | 0 | 6 (2.2) |
| Mental alteration | 0 | 0 | 3 (3.1) | 11 (12.2) | 0 | 0 | 14 (5.0) |
Abbreviations: HAdV, human adenovirus; IQR, interquartile range.
Clinical manifestations from hospitalized children infected with single HAdV‐3 and HAdV‐7, single and coinfection
| Clinical symptoms and signs | Single infection, n = 106, % | Coinfection, n = 173, % |
| Single HAdV‐3, n = 43, % | Single HAdV‐7, n = 34, % |
|
|---|---|---|---|---|---|---|
| Fever | 85 (80.2) | 130 (75.1) | 0.331 | 36 (83.7) | 30 (88.2) | 0.815 |
| High fever | 51 (48.1) | 84 (48.6) | 0.943 | 22 (12.7) | 21 (61.8) | 0.352 |
| Duration of fever >7 d | 21 (19.8) | 41 (23.7) | 0.448 | 8 (18.6) | 10 (29.4) | 0.266 |
| Duration of fever, IQR, d | 6 (4‐7.5) | 6 (3‐10) | 0.8 | 6 (4.25‐7.75) | 7 (5‐8.25) | 0.18 |
| Cough | 98 (92.5) | 162 (93.6) | 0.702 | 39 (90.7) | 31 (91.2) | 1 |
| Wheezing | 30 (28.3) | 76 (43.9) | 0.009 | 10 (23.3) | 11 (32.4) | 0.373 |
| Rales | 94 (88.7) | 151 (87.3) | 0.729 | 39 (90.7) | 32 (94.1) | 0.689 |
| Tachypnea | 16 (15.1) | 30 (17.3) | 0.624 | 6 (14.0) | 7 (20.6) | 0.44 |
| Cyanosis | 6 (5.7) | 13 (7.5) | 0.551 | 3 (7.0) | 3 (8.8) | 1 |
| Decreased breath sounds | 6 (5.7) | 8 (4.6) | 0.7 | 1 (2.3) | 2 (5.9) | 0.835 |
| Rash | 12 (11.3) | 13 (7.5) | 0.28 | 5 (11.6) | 4 (11.8) | 1 |
| Diarrhea | 12 (11.3) | 22 (12.7) | 0.729 | 5 (11.6) | 8 (23.5) | 0.166 |
| Vomiting | 12 (11.3) | 15 (8.7) | 0.467 | 3 (7.00) | 6 (17.7) | 0.276 |
| Seizure | 3 (2.8) | 3 (1.7) | 0.677 | 1 (2.3) | 0 | N |
| Mental alteration | 4 (3.8) | 10 (5.8) | 0.456 | 0 | 5 (14.7) | N |
Abbreviations: IQR, interquartile range; N, not applicable.
Demographic data of and outcome from hospitalized children infected with single HAdV‐3 infection and HAdV‐7 infection, single infection and coinfection
| Single infection, n = 106, % | Coinfection, n = 173, % |
| Single HAdV‐3,n = 43, % | Single HAdV‐7,n = 34, % |
| |
|---|---|---|---|---|---|---|
| Age, median (IQR), mo | 27.5 (12‐41) | 17 (9‐32.5) | 0.01 | 36 (13‐41) | 23.5 (8.75‐36) | 0.29 |
| <6 | 14 (13.2) | 26 (15.0) | 7 (16.3) | 3 (8.8) | ||
| 6‐12 | 11 (10.4) | 36 (20.8) | 3 (6.98) | 7 (20.6) | ||
| 13‐24 | 21 (19.8) | 41 (23.7) | 8 (18.6) | 7 (20.6) | ||
| 25‐36 | 13 (12.3) | 30 (17.3) | 3 (7.0) | 6 (17.7) | ||
| 37‐48 | 30 (28.3) | 15 (8.7) | 17 (39.5) | 8 (23.5) | ||
| 49‐60 | 8 (7.6) | 15 (8.7) | 1 (2.3) | 1 (2.9) | ||
| >60 | 9 (8.5) | 10 (5.8) | 0.007 | 4 (9.3) | 2 (5.9) | 0.47 |
| Male | 64 (60.4) | 112 (64.7) | 0.464 | 24 (55.8) | 20 (58.8) | 0.791 |
| Underlying disease | 6 (5.7) | 7 (4.1) | 0.361 | 3 (7.0) | 3 (8.8) | 1 |
| Lobe consolidation | 18 (17.0) | 26 (15.0) | 0.664 | 5 (11.6) | 12 (35.3) | 0.013 |
| Supplemental oxygen | 13 (12.3) | 31 (17.9) | 0.208 | 6 (14.0) | 9 (26.5) | 0.168 |
| Severe pneumonia | 12 (11.3) | 35 (20.2) | 0.054 | 5 (11.6) | 11 (32.4) | 0.031 |
| Admission to ICU | 6 (5.7) | 19 (11.0) | 0.131 | 3 (7.0) | 9 (26.5) | 0.019 |
| LOS, median (IQR), d | 7 (6‐9) | 8 (6‐10) | 0.023 | 7 (6‐8) | 9 (6.75‐11) | 0.03 |
Abbreviations: ICU, intensive care unit; IQR, interquartile range; LOS, length of hospital stay.
Figure 2Positive rate of 12 respiratory tract viruses in 4751 pediatric patients diagnosed with ALRTI in Hunan between September 2007 and March 2014. ALRTI, acute lower respiratory tract infections; HAdV, human adenovirus; HBoV, human bocavirus; HMPV, human metapneumovirus; HRV, human rhinovirus; IFVA, influenza virus; PIV1, parainfluenza virus type 1; RSV, respiratory syncytial virus